Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
National Cancer Institute (NCI)
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03300557
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Britt K Erickson

See list of participating sites